kidneyintelX.dkd评分在2型糖尿病合并CKD中的基线风险、纵向变化及与肾脏结局的关联
在CANVAS和CREDENCE试验中,评估基于生物标志物的风险评分kidneyintelX.dkd与肾脏结局的关联,并与KDIGO风险分类比较,同时考察其对卡格列净治疗的反应。结果显示该评分独立预测肾脏结局且优于KDIGO分类,卡格列净可显著降低评分,评分降低与后续肾脏风险降低相关。
要点
- kidneyintelX.dkd评分较KDIGO分类提供额外预后价值。
- 卡格列净治疗1年显著降低kidneyintelX.dkd评分。
- 评分降低与后续肾脏结局风险降低独立相关。
核心结论
- kidneyintelX.dkd评分在临床分类之外增加预后价值,反映卡格列净治疗反应,有助于识别最可能受益的患者。
研究设计与样本
- 基于CANVAS和CREDENCE两项大型随机对照试验,检测基线及第1年储存血浆中TNFR-1、TNFR-2和KIM-1,计算CKD G1-G3b参与者的kidneyintelX.dkd评分。
主要发现
- kidneyintelX.dkd评分随KDIGO风险类别升高而升高,但个体层面差异显示风险重分类改善。
- kidneyintelX.dkd评分与肾脏结局独立相关,且预测能力强于KDIGO分类。
- 第1年卡格列净较安慰剂显著降低kidneyintelX.dkd评分,且评分纵向降低与后续肾脏结局风险降低相关,独立于eGFR或UACR变化。
- 卡格列净的绝对风险降低在kidneyintelX.dkd高风险者中最大。
临床怎么用
- kidneyintelX.dkd评分可用于2型糖尿病合并CKD患者的个体化风险评估和监测,并帮助识别最可能从卡格列净治疗中获益者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the prognostic and clinical utility of kidneyintelX.dkd, a biomarker-based risk score, in patients with type 2 diabetes and a broad range of chronic kidney disease (CKD) by assessing its association with kidney outcomes at baseline and longitudinally, comparing it with the established Kidney Disease Improving Global Outcomes (KDIGO) risk classification, and examining its responsiveness to canagliflozin. RESEARCH DESIGN AND METHODS: We measured tumor necrosis factor receptor-1 (TNFR-1), TNFR-2, and kidney injury molecule-1 (KIM-1) in banked plasma samples at baseline and year 1 and calculated kidneyintelX.dkd scores of participants with CKD G1-G3b from two large randomized controlled trials (Canagliflozin Cardiovascular Assessment Study [CANVAS] and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation [CREDENCE]). We assessed concordance between KDIGO and kidneyintelX.dkd risk levels, evaluated associations of baseline and 1-year changes in kidneyintelX.dkd with kidney outcomes, and examined treatment effects of canagliflozin versus placebo. RESULTS: Mean kidneyintelX.dkd scores increased across higher KDIGO risk categories, but individual-level differences revealed improved risk reclassification. The kidneyintelX.dkd score was independently associated with kidney outcomes and more strongly predictive than KDIGO classification. At 1 year, canagliflozin significantly lowered kidneyintelX.dkd score versus placebo, and longitudinal reductions by 1 year were associated with lower subsequent risk of kidney outcomes, independent of changes in estimated glomerular filtration rate or urinary albumin-to-creatinine ratio. Absolute risk reductions with canagliflozin were largest among those at high kidneyintelX.dkd risk. CONCLUSIONS: The kidneyintelX.dkd score adds prognostic value beyond clinical classification, reflects canagliflozin treatment response, and helps identify individuals most likely to benefit from therapy. These findings support a role for the kidneyintelX.dkd score in personalized risk assessment and monitoring in type 2 diabetes and CKD in prospective studies and clinical practice.
引用
- Moedt E, Coca SG, Edwards K, et al. Baseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials. Diabetes Care. 2026. PMID: 41217780. doi:10.2337/dc25-1722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。